BIOHAVENJPM2025JAN12FINAL

© 2025 Biohaven, Ltd. All rights reserved.43rd Annual J.P.Morgan HealthcareConferenceJanuary 13, 2025Vlad Coric, M.D.Chairman and Chief Executive OfficerJENNIFER Living with SCA3Participant in the Troriluzole Clinical Study Forward-Looking StatementThis presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about Biohaven Ltd. (the “Company”) and our planned and ongoing clinical trials for our taldefgrobep alfa, troriluzole, BHV-2100, BHV-7000, BHV-8000, BHV-1300, BHV-1310, BHV-1510 and BHV-1530 development programs, the timing of and the availability of data from our clinical trials, the timing and our decisions to proceed with our planned regulatory filings, the timing of and our ability to obtain regulatory approvals for our product candidates, the clinical potential utility of our product candidates, alone and as compared to other existing potential treatment options, and the potential advan